What challenges did None face before AI implementation?

Algorithm bias leading to asymmetric treatment protocols. Regulatory compliance complexity, requiring adaptive AI systems. Shortage of AI-skilled workforce within the pharmaceutical industry. Data privacy and cybersecurity concerns when deploying AI. Resistance to technological change in traditional operations.

What was the impact of the AI solution?

AI adoption reported to reduce costs and boost customer satisfaction (confirmed by 75% CXOs). Improved trial planning and patient-centered healthcare methods. Accelerated drug discovery, reducing time to market. Enhanced operational efficiencies in manufacturing/supply chains.

Rank#2,167of 2,931

Source

MicrosoftLive source

EY-Parthenon and Microsoft boost AI adoption in Pharma

Use case typeDrug discoveryUpdated Jun 13, 2026

The joint EY-Parthenon and Microsoft report highlights AI’s transformational potential in the pharmaceutical sector and provides a comprehensive AI Maturity Framework to support widespread AI adoption. Reporting at BioAsia 2025, it reveals the steady integration of AI for drug discovery, manufacturing efficiencies, and patient-centered advancements. Featured challenges include algorithm bias, data security, workforce readiness, and regulatory hurdles, which are pivoted into opportunities for strategic growth. Innovations such as AI-optimized clinical trials and compliance automation were showcased, emphasizing the tool's potential to reshape life sciences operations.

Organization: None
Industry: Pharma
Location: India
Published: April 2025

Reported outcomes

−75%

costCost savings

Strategic outcomes

Risk & complianceAutomated regulatory compliance processesNew product / capabilityOptimized clinical trials and recruitmentNew product / capabilityAccelerated drug discovery and R&DSpeed & agilityCreated enterprise-wide AI scaling roadmap

Catalog median for cost savings deployments: −41% across 333 reported metrics. Compare benchmarks →

Primary read

Use case focus

Showing 3 of 3

1compliance automation
2clinical trial optimization
3predictive maintenance in medical devices

Algorithm bias leading to asymmetric treatment protocols.
Regulatory compliance complexity, requiring adaptive AI systems.
Shortage of AI-skilled workforce within the pharmaceutical industry.
Data privacy and cybersecurity concerns when deploying AI.
Resistance to technological change in traditional operations.

Developed AI-powered tools for regulatory compliance automation.
Implemented AI processes to optimize clinical trials and patient recruitment.
Promoted AI for accelerating drug discovery processes and R&D.
Introduced a structured roadmap for scaling AI enterprise-wide via Microsoft and EY.
Leveraged predictive maintenance and medical device modeling in MedTech.

Technologies

Azure AI Azure ML

AI adoption reported to reduce costs and boost customer satisfaction (confirmed by 75% CXOs).
Improved trial planning and patient-centered healthcare methods.
Accelerated drug discovery, reducing time to market.
Enhanced operational efficiencies in manufacturing/supply chains.

Architecture

EY-Parthenon and Microsoft’s framework categorizes organizations into AI Maturity levels and identifies their integration points: foundational, innovative, transformational. AI enables pharmaceutical R&D modeling, toxicity assessment, regulatory compliance. Optimized broader supply chain and MedTech innovation involve AI-first technical recalibrations.

Implementation partners1

EY-Parthenon

Sources & evidence2

Live sourceStill referenced

The case's original source is still reachable.